{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:04:30Z","timestamp":1778634270512,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T00:00:00Z","timestamp":1508976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Health\u2010related quality of life (HRQOL) in patients with chronic\u2010phase chronic myeloid leukemia (CML) is important because of the requirement for long\u2010term treatment. This study assessed HRQOL in bosutinib\u2010treated patients with Philadelphia chromosome\u2013positive CML and resistance or intolerance to 1 (chronic\u2010phase second\u2010line [CP2L]) or more (chronic\u2010phase third\u2010line [CP3L]) tyrosine kinase inhibitors who had 264 weeks or more of follow\u2010up (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier NCT00261846).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patient\u2010reported HRQOL was assessed with the EuroQol 5\u2010Dimensions Questionnaire (EQ\u20105D) and the Functional Assessment of Cancer Therapy\u2013Leukemia (FACT\u2010Leu).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In total, 284 and 119 patients composed the CP2L and CP3L cohorts, respectively. At treatment completion, more than 50% of the patients in the CP2L and CP3L cohorts completed the EQ\u20105D and FACT\u2010Leu assessments. The EQ\u20105D and EQ\u20105D visual analog scale scores were stable in both cohorts throughout treatment. The mean FACT\u2010Leu scores were generally stable over time but were lower in magnitude in the CP3L cohort versus the CP2L cohort. The FACT\u2010Leu scale scores of a subset of patients with chronic diarrhea (CP2L, n\u2009=\u2009101; CP3L, n\u2009=\u200930) were similar to the scores of the larger cohorts. Minimally important differences (MIDs) from baseline for the FACT\u2010Leu scale scores were observed for the following: emotional well\u2010being (EWB), Functional Assessment of Cancer Therapy\u2013General (FACT\u2010G) Total, FACT\u2010Leu Total, and Functional Assessment of Cancer Therapy Trial Outcome Index (FACT\u2010TOI) in the CP2L cohort and FACT\u2010Leu Total in the CP3L cohort. Among patients with chronic diarrhea, MIDs were observed for EWB, FACT\u2010G Total, FACT\u2010Leu Total, and FACT\u2010TOI in the CP2L cohort and for EWB, FACT\u2010G Total, and FACT\u2010Leu Total in the CP3L cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>HRQOL was maintained with long\u2010term bosutinib treatment for patients with CP2L and CP3L CML. <jats:bold><jats:italic>Cancer<\/jats:italic> 2018;124:587\u201095.<\/jats:bold> \u00a9 2017 The Authors. <jats:italic>Cancer<\/jats:italic> published by Wiley Periodicals, Inc. on behalf of <jats:italic>American Cancer Society<\/jats:italic>. This is an open access article under the terms of the Creative Commons Attribution\u2010NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.31082","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T09:18:07Z","timestamp":1509009487000},"page":"587-595","source":"Crossref","is-referenced-by-count":20,"title":["Long\u2010term patient\u2010reported outcomes from an open\u2010label safety and efficacy study of bosutinib in Philadelphia chromosome\u2013positive chronic myeloid leukemia patients resistant or intolerant to prior therapy"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M.","family":"Mamolo","sequence":"additional","affiliation":[{"name":"Pfizer Inc Groton Connecticut"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti\u2010Passerini","sequence":"additional","affiliation":[{"name":"University of Milano\u2010Bicocca Monza Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[{"name":"Hubertus Wald Tumor Center University Cancer Center Hamburg Hamburg Germany"},{"name":"University Hospital, Rheinisch\u2010Westf\u00e4lische Technische Hochscule Aachen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Su","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene L.","family":"Reisman","sequence":"additional","affiliation":[{"name":"Pfizer Inc New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Pfizer Inc Cambridge Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,26]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047266"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080689"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-277152"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-532341"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1630-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-167"},{"key":"e_1_2_8_15_1","volume-title":"Bosulif [full prescribing information]","year":"2014"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_8_17_1","unstructured":"LiptonJH CortesJE KhouryHJ et al.Long\u2010term bosutinib in patients with chronic phase chronic myeloid leukemia after prior imatinib failure. Paper presented at: Annual Meeting of the American Society of Clinical Oncology; May 29 to June 2 2015; Chicago IL."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23728"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13801"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.10.011"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1174108"},{"key":"e_1_2_8_22_1","volume-title":"EQ\u20105D\u20103L User Guide (Version 5.1)","author":"Reenan M","year":"2015"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2210"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513937"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.154"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-477687"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.170"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:39:18Z","timestamp":1760305158000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,26]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/cncr.31082"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31082","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,26]]}}}